Discounted Cash Flow (DCF) Analysis Unlevered
Creative Medical Technology Holding... (CELZ)
$0.467
-0.01 (-2.71%)
All numbers are in Millions, Currency in USD
Operating Data
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 0 | 0.12 | 0.17 | 0.16 | 0.09 | 0.63 | 4.54 | 32.67 | 234.99 | 1,690.45 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| EBITDA | -2.27 | -12.27 | -6.56 | -35.03 | 23.58 | -70.01 | -503.61 | -3,622.75 | -26,060.66 | -187,470.45 |
| EBITDA (%) | ||||||||||
| EBIT | -2.28 | -12.29 | -6.59 | -35.10 | 23.49 | -70.65 | -508.26 | -3,656.20 | -26,301.32 | -189,201.64 |
| EBIT (%) | ||||||||||
| Depreciation | 0.02 | 0.02 | 0.03 | 0.07 | 0.09 | 0.65 | 4.65 | 33.45 | 240.66 | 1,731.19 |
| Depreciation (%) |
Balance Sheet Data
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Total Cash | 0.01 | 0.30 | 0.09 | 0.10 | 10.72 | 16.24 | 116.83 | 840.41 | 6,045.59 | 43,489.64 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Cash (%) | ||||||||||
| Account Receivables | 0 | 0.01 | 0.01 | 0.06 | 0.03 | 0.23 | 1.68 | 12.10 | 87.04 | 626.15 |
| Account Receivables (%) | ||||||||||
| Inventories | - | - | - | - | 0.01 | 0.08 | 0.56 | 4.04 | 29.10 | 209.32 |
| Inventories (%) | ||||||||||
| Accounts Payable | 0.24 | 0.33 | 0.32 | 0.35 | 0.76 | 8.20 | 58.96 | 424.11 | 3,050.86 | 21,946.71 |
| Accounts Payable (%) | ||||||||||
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - |
| Capital Expenditure (%) |
Weighted Average Cost Of Capital
| Share price | $ 0.467 |
|---|---|
| Beta | 4.798 |
| Diluted Shares Outstanding | 0.58 |
| Cost of Debt | |
| Tax Rate | 0.00 |
| After-tax Cost of Debt | 5.00% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 26.129 |
| Total Debt | - |
| Total Equity | 0.27 |
| Total Capital | 0.27 |
| Debt Weighting | 0.00 |
| Equity Weighting | 100.00 |
| Wacc |
Build Up Free Cash
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 0 | 0.12 | 0.17 | 0.16 | 0.09 | 0.63 | 4.54 | 32.67 | 234.99 | 1,690.45 |
|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | -2.27 | -12.27 | -6.56 | -35.03 | 23.58 | -70.01 | -503.61 | -3,622.75 | -26,060.66 | -187,470.45 |
| EBIT | -2.28 | -12.29 | -6.59 | -35.10 | 23.49 | -70.65 | -508.26 | -3,656.20 | -26,301.32 | -189,201.64 |
| Tax Rate | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIAT | -2.28 | -12.29 | -6.59 | -35.10 | 23.49 | -70.65 | -508.26 | -3,656.20 | -26,301.32 | -189,201.64 |
| Depreciation | 0.02 | 0.02 | 0.03 | 0.07 | 0.09 | 0.65 | 4.65 | 33.45 | 240.66 | 1,731.19 |
| Accounts Receivable | - | -0 | 0 | -0.06 | 0.03 | -0.20 | -1.45 | -10.42 | -74.94 | -539.11 |
| Inventories | - | - | - | - | - | -0.07 | -0.48 | -3.48 | -25.05 | -180.22 |
| Accounts Payable | - | 0.09 | -0.01 | 0.03 | 0.41 | 7.43 | 50.76 | 365.15 | 2,626.75 | 18,895.85 |
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - |
| UFCF | - | - | - | - | - | -62.84 | -454.78 | -3,271.50 | -23,533.91 | -169,293.93 |
| WACC | ||||||||||
| PV UFCF | -49.82 | -285.87 | -1,630.39 | -9,298.66 | -53,033.39 | |||||
| SUM PV UFCF | -64,298.13 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 26.13 |
| Free cash flow (t + 1) | -172,679.81 |
| Terminal Value | -715,622.91 |
| Present Value of Terminal Value | -224,177.62 |
Intrinsic Value
| Enterprise Value | -288,475.76 |
|---|---|
| Net Debt | -10.72 |
| Equity Value | -288,465.03 |
| Shares Outstanding | 0.58 |
| Equity Value Per Share | -497,816.99 |